Printer Friendly

Zacks Analyst Blog Highlights: AtheroGenics, AstraZeneca, Campbell Soup and SAP.

CHICAGO -- announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AtheroGenics, Inc. (Nasdaq: AGIX), AstraZeneca (NYSE: AZN), Campbell Soup Company (NYSE: CPB) and SAP (NYSE: SAP).

See the latest posts to the Analyst Blog by visiting:

Here are highlights from Wednesday's Analyst Blog:

AtheroGenics Downgraded to Sell

AtheroGenics, Inc. (Nasdaq: AGIX) announced on March 19, 2007 that the ARISE phase III clinical study of AGI-1067 did not show a difference from placebo in its composite primary endpoint of time to first incidence of a composite of major adverse cardiovascular events (MACE). We expect development partner AstraZeneca (NYSE: AZN) to walk away from the collaboration within the next 45 days.

AtheroGenics could discontinue development of the candidate given the failed trial and potential safety concerns (liver function) that have materialized. Therefore, we see $2 as fair value.

Costs Keep Campbell's a Hold

Campbell Soup Company's (NYSE: CPB) Transformation and Driving Quality Growth Plans are improving the top-line through a combination of improved products, attractive packaging, a new retail shelving system and more effective marketing. Price increases in fiscal 2006 helped Campbell accomplish management's financial goals.

However, fiscal 2007 will see increased spending on marketing and the implementation of SAP (NYSE: SAP) in the United States, along with continued inflationary pressure from higher commodity costs. Hence, the Hold rating is maintained.

See the latest posts to the Analyst Blog by visiting

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Mar 29, 2007
Previous Article:Washington Group International, Inc. Chooses Bear Wagner Specialists to Trade Shares on NYSE.
Next Article:Pace Harmon Expands Presence with San Francisco Office.

Related Articles
Zacks Analyst Blog Highlights: JDA Software, SAP, Microsoft and Manpower.
Zacks Analyst Blog Highlights: Ariba, Aztar Corporation, OmniVision and SAP.
Zacks Analyst Blog Highlights: Hurray! Holding Co., China Mobile, ON Semiconductor, LSI Logic and Microsoft.
Zacks Analyst Blog Highlights: Schering-Plough, Merck, CNOOC and Sinopec.
Zacks Analyst Blog Highlights: Pozen, GlaxoSmithKline and Winston Hotels.
Zacks Analyst Blog Highlights: Abbott Labs, Boston Scientific, Johnson & Johnson, Motorola and Nokia.
Zacks Analyst Blog Highlights: Logitech, Microsoft and Pool Corporation.
Zacks Analyst Blog Highlights: SAP AG, Microsoft and Oracle.
Zacks Analyst Blog Highlights: aQuantive, Microsoft, Metabolix and Archer Daniels Midland.
Zacks Analyst Blog Highlights: ON Semiconductor, Microsoft, and WPP Group.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters